Transplantation Diagnostics Global Market - Forecast to 2022
Transplantation is a surgical procedure of transferring organ, tissue or cell taken from one part of the body and grafted into another area of the same individual or another individual of same species or different species. The solid organ, tissue and stem cell transplantation field has evolved from a clinical experiment to routine and reliable practice, which has proven to be clinically effective, life-saving and cost-effective. The transplantation diagnostics market is segmented based on the technology, product type, applications, end users and geography. By technology the market is divided into molecular and non-molecular methods. By application, the transplantation diagnostics market is divided into diagnostic and research segments. By product the transplantation diagnostics market is divided into instruments, consumables, software and services, assays and kits. By end users the transplantation market is segmented into hospital and transplant centres, Research laboratories and academic institutes. Geographical wise, the transplantation market is segmented into North America, Europe, Asia- Pacific and rest of the world.
Among the transplantation diagnostics by technology, the non-molecular method is dominating the market by occupying a largest share and the molecular method is expected to grow at a highest CAGR from 2015 to 2022. The transplantation diagnostics market by product type is segmented into three major divisions such as instruments, consumables and software & services. Among these, consumables accounts for largest share and is growing at a strong CAGR from 2015 to 2022. By applications, is segmented into two major divisions such as diagnostic and research. Among these, diagnostic accounts for largest share as well as fastest growing segment. The end-users market of transplantation diagnostics market is segmented into three major divisions, hospital & transplant centres, diagnostic laboratories and research laboratories & academic institutions. Among these, hospital and transplant centres accounts for largest share and growing at a strong CAGR.
The transplantation diagnostics market is expected to grow at a high double digit CAGR to reach $2,059.2 million by 2022. The factors driving the growth of this market are high incidence of organ and tissue transplantation procedures across the world, increasing geriatric population, coupled with an increasing population base for chronic disease, increasing healthcare awareness are likely to propel the market. In addition to this, increasing demand for early detection through non-invasive testing procedures like cell free DNA, increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to transplantation, high cost and non-affordability in developed as well as in low- and middle-income countries and unfavourable reimbursement policies are hampering the growth of the market. The threats for the transplantation diagnosticsmarket include the significant gap between the number of organs donated and the number of organs required.
The transplantation diagnostics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the transplantation diagnostics market include Abbott Laboratories, Inc. (U.S.), Biofortuna Ltd (U.K.), Bio-Rad Laboratories, Inc. (U.S.), CareDx, Inc. (U.S.), Illumina, Inc. (U.S.), Immucor, Inc.(U.S.), Linkage biosciences (U.S.), Qiagen N.V. (Netherlands), Roche (Switzerland), Thermo Fisher Scientific, Inc. (U.S.).
The report provides an in depth market analysis of the above mentioned segments across the following regions:
Among the transplantation diagnostics by technology, the non-molecular method is dominating the market by occupying a largest share and the molecular method is expected to grow at a highest CAGR from 2015 to 2022. The transplantation diagnostics market by product type is segmented into three major divisions such as instruments, consumables and software & services. Among these, consumables accounts for largest share and is growing at a strong CAGR from 2015 to 2022. By applications, is segmented into two major divisions such as diagnostic and research. Among these, diagnostic accounts for largest share as well as fastest growing segment. The end-users market of transplantation diagnostics market is segmented into three major divisions, hospital & transplant centres, diagnostic laboratories and research laboratories & academic institutions. Among these, hospital and transplant centres accounts for largest share and growing at a strong CAGR.
The transplantation diagnostics market is expected to grow at a high double digit CAGR to reach $2,059.2 million by 2022. The factors driving the growth of this market are high incidence of organ and tissue transplantation procedures across the world, increasing geriatric population, coupled with an increasing population base for chronic disease, increasing healthcare awareness are likely to propel the market. In addition to this, increasing demand for early detection through non-invasive testing procedures like cell free DNA, increase in the number of deals by collaborations and acquisitions to open an array of opportunities for the market to flourish are some of the opportunities that are propelling the growth of the market. However, lack of trained health care professionals, ethical issues related to transplantation, high cost and non-affordability in developed as well as in low- and middle-income countries and unfavourable reimbursement policies are hampering the growth of the market. The threats for the transplantation diagnosticsmarket include the significant gap between the number of organs donated and the number of organs required.
The transplantation diagnostics market is a highly competitive market and all the existing players in this market are involved in developing new and advanced assays to maintain their market shares. The major players in the transplantation diagnostics market include Abbott Laboratories, Inc. (U.S.), Biofortuna Ltd (U.K.), Bio-Rad Laboratories, Inc. (U.S.), CareDx, Inc. (U.S.), Illumina, Inc. (U.S.), Immucor, Inc.(U.S.), Linkage biosciences (U.S.), Qiagen N.V. (Netherlands), Roche (Switzerland), Thermo Fisher Scientific, Inc. (U.S.).
The report provides an in depth market analysis of the above mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increase in the rate of solid organ, tissue and stem cell transplantation
3.3.1.2 Increase in geriatric population coupled with chronic diseases
3.3.1.3 Increase in research grants and funding
3.3.1.4 Increasing demand for early detection through non-invasive testing
procedures using cell-free DNA
3.3.1.5 Growing awareness among people for organ donation and increase in
healthcare expenditure
3.3.1.6 Technological shift from serological assays to gene-based HLA profiling
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High device cost and non-affordability
3.3.2.2 Limited medical reimbursements for organ donation and transplantation procedures
3.3.2.3 Ethical issues related to transplantation
3.3.2.4 Significant gap between the number of organs donated and the number of organs required annually is a major challenge limiting the growth of the global transplant diagnostic market
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 INDIA
3.4.4 CHINA
3.4.5 JAPAN
3.5 PORTERS FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 COMPETITIVE RIVALRY
3.5.4 BARGAINING POWER OF SUPPLIERS
3.5.5 BARGAINING POWER OF BUYERS
3.6 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7 RECENT AND UPCOMING PRODUCTS
4 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 MOLECULAR METHODS
4.2.1 PCR BASED MOLECULAR METHODS
4.2.1.1 SSP-PCR
4.2.1.2 SSO-PCR
4.2.1.3 Others
4.2.1.3.1 SNP-PCR
4.2.1.3.2 RFLP-PCR
4.2.2 SEQUENCING BASED MOLECULAR METHODS
4.2.2.1 NGS
4.2.2.2 SANGER SEQUENCING
4.3 NON-MOLECULAR METHODS
4.3.1 SEROLOGICAL TESTS
4.3.2 MIXED LYMPHOCYTE CULTURE ASSAY
4.3.3 FLOW CYTOMETRY
5 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY PRODUCT TYPE
5.1 INTRODUCTION
5.2 INSTRUMENTS
5.3 CONSUMABLES
5.4 SOFTWARE & SERVICES
6 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY SCREENING METHODS
6.1 INTRODUCTION
6.2 PRE-TRANSPLANTATION SCREENING
6.3 POST-TRANSPLANTATION SCREENING
7 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DIAGNOSTIC (MEDICAL) APPLICATION
7.2.1 SOLID ORGAN TRANSPLANTATION DIAGNOSTICS
7.2.1.1 Kidney Transplantation
7.2.1.2 Heart Transplantation
7.2.1.3 Liver Transplantation
7.2.1.4 Other Transplantation
7.2.2 STEM CELL TRANSPLANTATION
7.2.3 TISSUE BASED TRANSPLANTATION
7.3 RESEARCH APPLICATIONS
8 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY END-USERS
8.1 INTRODUCTION
8.2 HOSPITALS AND TRANSPLANT CENTRES
8.3 DIAGNOSTIC LABORATORIES
8.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS
9 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 SPAIN
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 AUSTRALIA
9.5 REST OF THE WORLD
10 COMPANY DEVELOPMENTS
10.1 INTRODUCTION
10.1.1 ACQUISTIONS & AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS A MAJOR GROWTH STRATEGY OF TRANSPLANTATION DIAGNOSTICS MARKET PLAYERS
10.2 ACQUISITIONS
10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
10.4 NEW PRODUCT LAUNCH
10.5 APPROVALS
10.6 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 ABBOTT LABORATORIES, INC.
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BIOFORTUNA LTD
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BIO-RAD LABORATORIES
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 CAREDX, INC.
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 ILLUMINA, INC.
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 IMMUCOR, INC.
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 LINKAGE BIOSCIENCES, INC.
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 QIAGEN N.V.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 ROCHE HOLDINGS AG
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 THERMO FISHER SCIENTIFIC, INC.
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increase in the rate of solid organ, tissue and stem cell transplantation
3.3.1.2 Increase in geriatric population coupled with chronic diseases
3.3.1.3 Increase in research grants and funding
3.3.1.4 Increasing demand for early detection through non-invasive testing
procedures using cell-free DNA
3.3.1.5 Growing awareness among people for organ donation and increase in
healthcare expenditure
3.3.1.6 Technological shift from serological assays to gene-based HLA profiling
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High device cost and non-affordability
3.3.2.2 Limited medical reimbursements for organ donation and transplantation procedures
3.3.2.3 Ethical issues related to transplantation
3.3.2.4 Significant gap between the number of organs donated and the number of organs required annually is a major challenge limiting the growth of the global transplant diagnostic market
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 INDIA
3.4.4 CHINA
3.4.5 JAPAN
3.5 PORTERS FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 COMPETITIVE RIVALRY
3.5.4 BARGAINING POWER OF SUPPLIERS
3.5.5 BARGAINING POWER OF BUYERS
3.6 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7 RECENT AND UPCOMING PRODUCTS
4 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.2 MOLECULAR METHODS
4.2.1 PCR BASED MOLECULAR METHODS
4.2.1.1 SSP-PCR
4.2.1.2 SSO-PCR
4.2.1.3 Others
4.2.1.3.1 SNP-PCR
4.2.1.3.2 RFLP-PCR
4.2.2 SEQUENCING BASED MOLECULAR METHODS
4.2.2.1 NGS
4.2.2.2 SANGER SEQUENCING
4.3 NON-MOLECULAR METHODS
4.3.1 SEROLOGICAL TESTS
4.3.2 MIXED LYMPHOCYTE CULTURE ASSAY
4.3.3 FLOW CYTOMETRY
5 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY PRODUCT TYPE
5.1 INTRODUCTION
5.2 INSTRUMENTS
5.3 CONSUMABLES
5.4 SOFTWARE & SERVICES
6 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY SCREENING METHODS
6.1 INTRODUCTION
6.2 PRE-TRANSPLANTATION SCREENING
6.3 POST-TRANSPLANTATION SCREENING
7 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DIAGNOSTIC (MEDICAL) APPLICATION
7.2.1 SOLID ORGAN TRANSPLANTATION DIAGNOSTICS
7.2.1.1 Kidney Transplantation
7.2.1.2 Heart Transplantation
7.2.1.3 Liver Transplantation
7.2.1.4 Other Transplantation
7.2.2 STEM CELL TRANSPLANTATION
7.2.3 TISSUE BASED TRANSPLANTATION
7.3 RESEARCH APPLICATIONS
8 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY END-USERS
8.1 INTRODUCTION
8.2 HOSPITALS AND TRANSPLANT CENTRES
8.3 DIAGNOSTIC LABORATORIES
8.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS
9 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 SPAIN
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 AUSTRALIA
9.5 REST OF THE WORLD
10 COMPANY DEVELOPMENTS
10.1 INTRODUCTION
10.1.1 ACQUISTIONS & AGREEMENTS, COLLABORATIONS & PARTNERSHIPS AS A MAJOR GROWTH STRATEGY OF TRANSPLANTATION DIAGNOSTICS MARKET PLAYERS
10.2 ACQUISITIONS
10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
10.4 NEW PRODUCT LAUNCH
10.5 APPROVALS
10.6 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 ABBOTT LABORATORIES, INC.
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BIOFORTUNA LTD
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BIO-RAD LABORATORIES
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 CAREDX, INC.
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 ILLUMINA, INC.
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 IMMUCOR, INC.
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 LINKAGE BIOSCIENCES, INC.
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 QIAGEN N.V.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 ROCHE HOLDINGS AG
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 THERMO FISHER SCIENTIFIC, INC.
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
LIST OF TABLES
Table 1 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 2 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 3 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 4 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 5 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 6 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 7 MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 8 MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 9 PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 10 PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 11 SSP-PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 12 SSO-PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 13 OTHERS BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 14 SEQUENCING BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 15 SEQUENCING BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 16 NGS BASED MOLECUAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 17 SANGER BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 18 NON-MOLECULAR METHODS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 19 NON-MOLECULAR METHODS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 20 SEROLOGICAL TESTS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 21 MIXED LYMPHOCYTE CULTURE ASSAY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 22 FLOW CYTOMETRY BASED NON-MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 23 TRANSPLANTATION DIAGNOSTICS GLOBALMARKET, BY PRODUCTS, (2014-2022) ($MN)
Table 24 INSTRUMENTS GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
Table 25 CONSUMABLES GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
Table 26 SOFTWARE & SERVICES GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
Table 27 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 28 PRE-TRANSPLANTATION SCREENING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 29 POST-TRANSPLANTATION SCREENING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 30 TRANSPLANT DIAGNOSTIC GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 31 DIAGNOSTICS (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY TYPE (2014-2022) ($MN)
Table 32 DIAGNOSTICS (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 33 SOLID ORGAN TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 34 SOLID ORGAN TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 35 KIDNEY TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 36 HEART TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 37 LIVER TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 38 OTHER TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 39 STEM CELL TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 40 TISSUE BASED TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 41 RESEARCH APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 42 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 43 HOSPITALS AND TRANSPLANT CENTRES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 44 DIAGNOSTIC LABORATRIES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 45 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 46 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 47 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 48 NORTH AMERICAN MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 49 NORTH AMERICAN PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 50 NORTH AMERICAN SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 51 NORTH AMERICAN NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 52 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 53 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 54 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 55 NORTH AMERICAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 56 NORTH AMERICAN SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 57 NORTH AMERICAN TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 58 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 59 EUROPEAN MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 60 EUROPEAN PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 61 EUROPEAN SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 62 EUROPEAN NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 63 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 64 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 65 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 66 EUROPEAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 67 EUROPEAN SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 68 EUROPEAN TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 69 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 70 ASIA-PACIFIC MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 71 ASIA-PACIFIC PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 72 ASIA-PACIFIC SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 73 ASIA-PACIFIC NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 74 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 75 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 76 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 77 ASIA-PACIFIC DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 78 ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 79 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 80 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 81 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 82 REST OF THE WORLD PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 83 REST OF THE WORLD SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 84 REST OF THE WORLD NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 85 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 86 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 87 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 88 REST OF THE WORLD DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 89 REST OF THE WORLD SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 90 REST OF THE WORLD TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 91 ACQUISITIONS (2014-2016)
Table 92 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2016)
Table 93 NEW PRODUCT LAUNCHES (2014-2016)
Table 94 APPROVALS, (2014-2016)
Table 95 OTHER DEVELOPMENTS (2014-2016)
Table 96 ABBOTT LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 97 ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 98 ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 99 BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 100 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 101 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 102 CAREDX, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 103 ILLUMINA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 104 ILLUMINA, INC.: TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
Table 105 ILLUMINA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 106 IMMUCOR, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 107 IMMUCOR, INC.: TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
Table 108 IMMUCOR, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 109 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 110 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 111 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 112 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 113 ROCHE HOLDINGS AG:TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
Table 114 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2013-2015) ($MN)
Table 115 ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 116 THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 117 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 118 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 1 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 2 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 3 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 4 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 5 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 6 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 7 MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 8 MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 9 PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 10 PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 11 SSP-PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 12 SSO-PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 13 OTHERS BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 14 SEQUENCING BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 15 SEQUENCING BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 16 NGS BASED MOLECUAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 17 SANGER BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 18 NON-MOLECULAR METHODS GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 19 NON-MOLECULAR METHODS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 20 SEROLOGICAL TESTS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 21 MIXED LYMPHOCYTE CULTURE ASSAY GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 22 FLOW CYTOMETRY BASED NON-MOLECULAR METHOD GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 23 TRANSPLANTATION DIAGNOSTICS GLOBALMARKET, BY PRODUCTS, (2014-2022) ($MN)
Table 24 INSTRUMENTS GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
Table 25 CONSUMABLES GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
Table 26 SOFTWARE & SERVICES GLOBAL MARKET, BY REGION, (2014-2022) ($MN)
Table 27 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 28 PRE-TRANSPLANTATION SCREENING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 29 POST-TRANSPLANTATION SCREENING GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 30 TRANSPLANT DIAGNOSTIC GLOBAL MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 31 DIAGNOSTICS (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY TYPE (2014-2022) ($MN)
Table 32 DIAGNOSTICS (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 33 SOLID ORGAN TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 34 SOLID ORGAN TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 35 KIDNEY TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 36 HEART TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 37 LIVER TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 38 OTHER TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 39 STEM CELL TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 40 TISSUE BASED TRANSPLANTATION APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 41 RESEARCH APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 42 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 43 HOSPITALS AND TRANSPLANT CENTRES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 44 DIAGNOSTIC LABORATRIES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 45 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 46 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 47 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 48 NORTH AMERICAN MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 49 NORTH AMERICAN PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 50 NORTH AMERICAN SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 51 NORTH AMERICAN NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 52 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 53 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 54 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 55 NORTH AMERICAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 56 NORTH AMERICAN SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 57 NORTH AMERICAN TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 58 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 59 EUROPEAN MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 60 EUROPEAN PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 61 EUROPEAN SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 62 EUROPEAN NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 63 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 64 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 65 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 66 EUROPEAN DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 67 EUROPEAN SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 68 EUROPEAN TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 69 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 70 ASIA-PACIFIC MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 71 ASIA-PACIFIC PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 72 ASIA-PACIFIC SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 73 ASIA-PACIFIC NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 74 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 75 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 76 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 77 ASIA-PACIFIC DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 78 ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 79 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 80 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, (2014-2022) ($MN)
Table 81 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MOLECULAR METHOD MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 82 REST OF THE WORLD PCR BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 83 REST OF THE WORLD SEQUENCING BASED MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 84 REST OF THE WORLD NON-MOLECULAR METHODS MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 85 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY SCREENING METHODS, (2014-2022) ($MN)
Table 86 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2014-2022) ($MN)
Table 87 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY APPLICATION, (2014-2022) ($MN)
Table 88 REST OF THE WORLD DIAGNOSTIC APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 89 REST OF THE WORLD SOLID ORGAN TRANSPLANTATION APPLICATION MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 90 REST OF THE WORLD TRANSPLANT DIAGNOSTICS MARKET REVENUE, BY END-USERS, (2014-2022) ($MN)
Table 91 ACQUISITIONS (2014-2016)
Table 92 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2014-2016)
Table 93 NEW PRODUCT LAUNCHES (2014-2016)
Table 94 APPROVALS, (2014-2016)
Table 95 OTHER DEVELOPMENTS (2014-2016)
Table 96 ABBOTT LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 97 ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 98 ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 99 BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 100 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 101 BIO-RAD LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 102 CAREDX, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 103 ILLUMINA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 104 ILLUMINA, INC.: TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
Table 105 ILLUMINA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 106 IMMUCOR, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 107 IMMUCOR, INC.: TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
Table 108 IMMUCOR, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 109 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 110 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 111 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 112 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 113 ROCHE HOLDINGS AG:TOTAL REVENUE BY SEGMENTS, (2013-2015) ($MN)
Table 114 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2013-2015) ($MN)
Table 115 ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 116 THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 117 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 118 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
LIST OF FIGURES
Figure 1 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Figure 2 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: RESEARCH METHODOLOGY
Figure 3 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
Figure 5 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
Figure 6 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
Figure 9 TRANSPLANTATION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
Figure 10 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2015 V’S 2022) ($MN)
Figure 11 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY MOLECUAR METHODS, (2015 V’S 2022) ($MN)
Figure 12 PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 13 SEQUENCING BASED MOLECUAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 14 NON-MOLECUAR METHODS GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 15 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2015 V’S 2022) ($MN)
Figure 16 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY SCREENING METHODS, (2015 V’S 2022) ($MN)
Figure 17 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 18 DIAGNOSTIC (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 19 SOLID ORGAN TRANSPLANTATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 20 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2015 V’S 2022) ($MN)
Figure 21 TRANSPLANTATION DIANOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Figure 22 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
Figure 23 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
Figure 24 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS (2015 V’S 2022) ($MN)
Figure 25 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
Figure 26 KEY GROWTH STRATEGIES, (2014-2016)
Figure 27 SWOT: ABBOTT LABORATORIES, INC.
Figure 28 SWOT: BIOFORTUNA LTD
Figure 29 SWOT: BIO-RAD LABORATORIES
Figure 30 SWOT: CAREDX, INC.
Figure 31 SWOT: ILLUMINA, INC.
Figure 32 SWOT: IMMUCOR, INC.
Figure 33 SWOT: LINKAGE BIOSCIENCES
Figure 34 SWOT: QIAGEN N.V.
Figure 35 SWOT: ROCHE HOLDINGS AG
Figure 36 SWOT: THERMO FISHER SCIENTIFIC
Figure 1 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2014-2022) ($MN)
Figure 2 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: RESEARCH METHODOLOGY
Figure 3 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
Figure 5 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
Figure 6 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
Figure 9 TRANSPLANTATION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
Figure 10 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2015 V’S 2022) ($MN)
Figure 11 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY MOLECUAR METHODS, (2015 V’S 2022) ($MN)
Figure 12 PCR BASED MOLECULAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 13 SEQUENCING BASED MOLECUAR METHOD GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 14 NON-MOLECUAR METHODS GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 15 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2015 V’S 2022) ($MN)
Figure 16 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY SCREENING METHODS, (2015 V’S 2022) ($MN)
Figure 17 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2015 V’S 2022) ($MN)
Figure 18 DIAGNOSTIC (MEDICAL) APPLICATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 19 SOLID ORGAN TRANSPLANTATION GLOBAL MARKET REVENUE, BY TYPE, (2015 V’S 2022) ($MN)
Figure 20 TRANSPLANT DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2015 V’S 2022) ($MN)
Figure 21 TRANSPLANTATION DIANOSTICS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Figure 22 NORTH AMERICAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
Figure 23 EUROPEAN TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
Figure 24 ASIA-PACIFIC TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS (2015 V’S 2022) ($MN)
Figure 25 REST OF THE WORLD TRANSPLANTATION DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY, PRODUCTS, APPLICATION & END-USERS, (2015 V’S 2022) ($MN)
Figure 26 KEY GROWTH STRATEGIES, (2014-2016)
Figure 27 SWOT: ABBOTT LABORATORIES, INC.
Figure 28 SWOT: BIOFORTUNA LTD
Figure 29 SWOT: BIO-RAD LABORATORIES
Figure 30 SWOT: CAREDX, INC.
Figure 31 SWOT: ILLUMINA, INC.
Figure 32 SWOT: IMMUCOR, INC.
Figure 33 SWOT: LINKAGE BIOSCIENCES
Figure 34 SWOT: QIAGEN N.V.
Figure 35 SWOT: ROCHE HOLDINGS AG
Figure 36 SWOT: THERMO FISHER SCIENTIFIC
